Medical Economics January 20, 2025
Key Takeaways
- The Medicare Part D Drug Price Negotiation Program aims to lower drug costs, but concerns exist about its impact on beneficiaries and drug innovation.
- Critics argue the program benefits the federal government more than Medicare beneficiaries, lacking mechanisms to pass savings to patients.
- Concerns about transparency and potential utilization management abuse have been raised, with calls for CMS to ensure patient access and cost-savings.
- The program’s future and effectiveness in delivering lower drug prices remain uncertain, especially under different political administrations.
Democrats claim credit, vow to fight against repeal; patient advocacy group offers critique.
The Medicare Part D Drug Price Negotiation Program generally earned praise upon releasing the latest list of 15 drugs that will be...
Today's Sponsors
Today's Sponsor
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech